Cholic acid (Orphacol) - Laboratoires CTRS

Drug Profile

Cholic acid (Orphacol) - Laboratoires CTRS

Alternative Names: Orphacol

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratoires CTRS
  • Developer Laboratoires CTRS; Medical Need
  • Class Choleretics; Cholic acids; Gallstone therapies; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor modulators; Sodium-bile acid cotransporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Inborn genetic disorders

Most Recent Events

  • 15 Feb 2017 Zaphyr Pharmaceuticals and Laboratoires CTRS enter into supply and distribution agreement for Cholic acid (Orphacol) in Middle East and North Africa for Inborn genetic disorders
  • 31 May 2016 Launched for Inborn genetic disorders in Germany (PO) before May 2016
  • 12 Sep 2013 Registered for Inborn genetic disorders (inborn errors in primary bile acid synthesis) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top